FAQ/Help |
Calendar |
Search |
Today's Posts |
08-28-2019, 08:44 PM | #1 | ||
|
|||
Senior Member
|
My thanks to Iqbal at HU for pointing me at this news.
The FDA "has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes. Istradefylline is a selective adenosine A2A receptor antagonist." [1] Istradefylline has been around for years. It was well covered in the early days of the forum, but nothing for the last 5 years. Efficacy for those concurrently taking L/C was: "The pooled analysis included 2719 treated patients (placebo, n=992; 20 mg/day, n=848; 40 mg/day, n=879). At week 12, OFF-hours/day with 20 and 40mg istradefylline was reduced (LS mean difference from placebo in reduction from baseline [95%CI], −0.38 [−0.61, −0.15] and −0.45 [−0.68, −0.22], respectively) long half-life (>60 h) At steady state, istradefylline exposure increased by 35% in the presence of Cyp3A4 inhibitors" [2] But, what really interests me is: "It is estimated that the caffeine intake from a cup of coffee would only lead to 20% occupation of A2A receptors" [3] So, a cup of coffee gives just a few minutes more "on" time. But, with the long half-life this is good quality time and it may be additive. References: [1] FDA OKs Istradefylline for Parkinson's Disease 'Off' Episodes [2] A Pooled Analysis for Eight Randomized Controlled Trials of Istradefylline, an Adenosine A2A Receptor Antagonist: Efficacy as Adjunct to Levodopa in Parkinson’s Disease (PD) (P3.8- 3 ) | Neurology [3] Client Request Error John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
"Thanks for this!" says: | eds195 (08-31-2019) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Istradefylline clinical trial results for Parkinson's Disease | Parkinson's Disease | |||
istradefylline (KW-6002) not approved | Parkinson's Disease Clinical Trials | |||
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson dise | Parkinson's Disease | |||
Not Approvable Letter from FDA for Istradefylline (KW-6002) | Parkinson's Disease | |||
Istradefylline (KW-6002)...FDA Not Approvable Letter | Parkinson's Disease Clinical Trials |